Halozyme Capital Surpluse vs Total Liab Analysis
HALO Stock | USD 44.29 0.94 2.17% |
Halozyme Therapeutics financial indicator trend analysis is much more than just examining Halozyme Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Halozyme Therapeutics is a good investment. Please check the relationship between Halozyme Therapeutics Capital Surpluse and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
Capital Surpluse vs Total Liab
Capital Surpluse vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Halozyme Therapeutics Capital Surpluse account and Total Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Halozyme Therapeutics' Capital Surpluse and Total Liab is -0.67. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Liab in the same time period over historical financial statements of Halozyme Therapeutics, assuming nothing else is changed. The correlation between historical values of Halozyme Therapeutics' Capital Surpluse and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Halozyme Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Capital Surpluse i.e., Halozyme Therapeutics' Capital Surpluse and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.67 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Capital Surpluse
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Halozyme Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Halozyme Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.At this time, Halozyme Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Tax Provision is likely to grow to about 70.1 M, while Sales General And Administrative To Revenue is likely to drop 0.44.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 361.9M | 520.8M | 636.9M | 668.7M | Total Revenue | 443.3M | 660.1M | 829.3M | 870.7M |
Halozyme Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Halozyme Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Halozyme Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 565.9M | 579.9M | 1.1B | 1.8B | 1.7B | 1.8B | |
Other Current Liab | 55.6M | 20.5M | 24.4M | 96.5M | 100.7M | 105.7M | |
Total Current Liabilities | 85.6M | 421.4M | 117.1M | 130.8M | 112.5M | 67.5M | |
Total Stockholder Equity | 91.8M | 151.0M | 197.0M | 169.8M | 83.8M | 66.9M | |
Net Debt | 282.4M | 249.5M | 758.0M | 1.3B | 1.4B | 1.4B | |
Retained Earnings | (603.7M) | (474.6M) | (58.9M) | 143.2M | 90.6M | 95.1M | |
Cash | 120.2M | 147.7M | 118.7M | 234.2M | 118.4M | 81.7M | |
Cash And Short Term Investments | 421.3M | 368.0M | 740.9M | 362.8M | 336M | 196.9M | |
Common Stock Total Equity | 145K | 137K | 135K | 138K | 155.3K | 104.5K | |
Common Stock Shares Outstanding | 144.3M | 141.5M | 146.8M | 140.6M | 134.2M | 104.7M | |
Liabilities And Stockholders Equity | 565.9M | 579.9M | 1.1B | 1.8B | 1.7B | 1.8B | |
Other Stockholder Equity | 695.1M | 625.5M | 256.3M | 27.4M | 2.4M | 2.3M | |
Total Liab | 474.1M | 428.9M | 907.5M | 1.7B | 1.6B | 1.7B | |
Total Current Assets | 543.4M | 554.8M | 926.3M | 739.0M | 746.4M | 783.7M | |
Common Stock | 145K | 137K | 135K | 138K | 127K | 106.0K | |
Short Long Term Debt Total | 402.6M | 397.2M | 876.7M | 1.5B | 1.5B | 1.6B | |
Accounts Payable | 6.4M | 1.9M | 1.5M | 17.7M | 11.8M | 12.4M | |
Property Plant And Equipment Net | 10.9M | 10.6M | 8.8M | 75.6M | 74.9M | 78.7M | |
Non Current Assets Total | 22.4M | 25.2M | 178.1M | 1.1B | 986.8M | 1.0B | |
Non Currrent Assets Other | 11.1M | 14.1M | 13.9M | 26.3M | 17.8M | 9.0M | |
Other Assets | 11.6M | 14.6M | 169.3M | 71.2M | 81.9M | 86.0M | |
Inventory | 29.4M | 60.7M | 53.9M | 100.1M | 127.6M | 134.0M | |
Other Current Assets | 33.4M | 28.3M | 40.5M | 45.0M | 48.6M | 51.0M | |
Property Plant And Equipment Gross | 10.9M | 10.6M | 21.9M | 90.3M | 94.6M | 99.3M | |
Accumulated Other Comprehensive Income | 240K | 22K | (620K) | (922K) | (9.3M) | (8.8M) | |
Property Plant Equipment | 10.9M | 10.6M | 8.8M | 75.6M | 86.9M | 91.3M | |
Current Deferred Revenue | 4.2M | 4.0M | 1.7M | 3.2M | (32.2M) | (30.6M) | |
Net Receivables | 59.4M | 97.7M | 91.0M | 231.1M | 234.2M | 245.9M | |
Other Liab | 2.3M | 7.5M | 3.1M | 17.7M | 16.0M | 26.6M | |
Non Current Liabilities Total | 388.5M | 7.5M | 790.3M | 1.5B | 1.5B | 1.6B | |
Net Tangible Assets | 90.5M | 155.1M | 197.0M | (783.7M) | (705.3M) | (670.0M) | |
Long Term Debt | 34.9M | 383.0M | 787.3M | 1.5B | 1.5B | 1.6B | |
Retained Earnings Total Equity | (603.7M) | (474.6M) | (58.9M) | 143.2M | 164.7M | 172.9M | |
Short Term Investments | 301.1M | 220.3M | 622.2M | 128.6M | 217.6M | 203.8M | |
Capital Surpluse | 695.1M | 625.5M | 256.3M | 27.4M | 31.5M | 29.9M | |
Long Term Debt Total | 34.9M | 383.0M | 787.3M | 1.5B | 1.7B | 1.8B | |
Non Current Liabilities Other | 4.2M | 3.5M | 544K | 45.9M | 37.7M | 39.6M | |
Short Long Term Debt | 19.5M | 397.2M | 89.4M | 13.3M | 15.3M | 14.6M | |
Short Term Debt | 19.5M | 397.2M | 89.4M | 13.3M | 32.2M | 30.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share 2.41 | Revenue Per Share 6.643 | Quarterly Revenue Growth 0.208 | Return On Assets 0.1348 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.